Inhibrx Biosciences, Inc.
Financials
Valuation Metrics
Inhibrx Biosciences, Inc.'s Market Cap is $1.06B. At end of 2025 it was $1.22B. Ranked #2381 of 3,116 in US market (top 76%), #963 of 1,472 on NASDAQ (top 65%), #176 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.06B | US#2,381/3,116 Sec#176/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-138M | US—/3,116 Sec—/265 |
| Total Assets | $154M | US#3,016/3,116 Sec#252/265 |
| Net Assets | $-53M | US#2,942/3,116 Sec#246/265 |
| Employees | 110 | US#2,593/3,116 Sec#169/265 |
| Value | ||
| P/S | 814.03x | US#2,981/3,116 Sec#195/265 |
| FCF Yield | -12.46% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -89.60% | US#3,045/3,116 Sec#251/265 |
| Revenue Growth | -100.00% | US#2,726/3,116 Sec#182/265 |
| Financial Health | ||
| Total Debt | $5M | US#2,886/3,116 Sec#212/265 |
| FCF | $-132M | US#2,693/3,116 Sec#167/265 |
| Cash | $133M | US#2,028/3,116 Sec#146/265 |
| Current Ratio | 5.07x | US#457/3,116 Sec#140/265 |
| Performance | ||
| 1Y Return | -11.67% | US#1,976/3,116 Sec#160/265 |
| 1M Return | -25.63% | US#3,021/3,116 Sec#250/265 |
| From 52W High | -53.55% | US#2,721/3,116 Sec#208/265 |
| 1Y MDD | -49.39% | US#2,333/3,116 Sec#152/265 |
| Trading | ||
| Volume | 208,255 shares | US#2,326/3,116 Sec#223/265 |
| Trading Value | $15M | US#1,753/3,116 Sec#132/265 |
| Per Share | ||
| EPS | $-9.42 | US—/3,116 Sec—/265 |
| BPS | $-3.61 | US—/3,116 Sec—/265 |
Company Info
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.